Mochi Health vs Found Weight Loss 2026
An independent, side-by-side comparison of Mochi Health and Found for GLP-1 weight loss programs — pricing, medications, protocols, and patient experience.

Quick Verdict
Best Price
Found
Starting at $159/mo vs $Infinity/mo
Most Medications
Mochi Health
2 medications vs 2
Best for Beginners
Mochi Health
Hybrid, fast onboarding
Head-to-Head Comparison
Pricing Breakdown
Side-by-side pricing for every medication.
| Medication | Mochi Health | Found | Savings |
|---|---|---|---|
| Semaglutide | Not offered | $159/monthly | Only at Found |
| Tirzepatide | Not offered | $399/monthly | Only at Found |
Pros and Cons
Mochi Health
- Video consultations with board-certified obesity medicine providers
- Registered dietitian access included in membership
- Orforglipron (oral GLP-1) available at $149/mo
- Brand-name injectable GLP-1s available through insurance, plus non-GLP-1 alternatives
- Insurance support with prior authorization handling
- Available in 49 states
- Membership fee is required on top of medication cost
- Lab work not included (recommended but at additional cost)
- Some patients have reported shipping delays
- Early-stage company with limited funding (~$1M raised) compared to established players
- Compounded GLP-1 options permanently unavailable
- Not available in Alabama
Found
- Holistic approach — medication + coaching + community
- Board-certified obesity medicine specialists
- Competitive compounded semaglutide pricing
- Personalized weight-loss plans with behavior change focus
- Slower shipping than competitors (5-7 days)
- No lab testing included
- Coaching quality can vary
- Limited to weight-loss medications only
How They Compare
Our editorial assessment across key dimensions.
In-Depth Comparison
By sarah-chen · Last updated March 30, 2026
Mochi Health vs Found Weight Loss: Specialist Care vs Coaching Program (2026)
Medically reviewed by Telehealth Ally Medical Review Team. Pricing and protocol data last verified April 2026.
Mochi Health and Found cost roughly the same all-in. Both use board-certified obesity medicine physicians. Both offer GLP-1 medications. The difference is what surrounds the prescription.
Mochi is built around synchronous video consultations with obesity specialists and a flat-rate medication model. Found is built around behavioral coaching alongside medication, on the premise that a prescription alone won't produce lasting weight loss.
If you're deciding between them, the question is whether you need specialist clinical oversight or structured behavior-change support. For a broader look at your options, see our GLP-1 telehealth provider comparison.
Quick verdict: which should you choose?
Choose Mochi Health if: You have a complex metabolic history, you've failed prior weight loss attempts, or you want a board-certified obesity specialist conducting real video consultations — not just reviewing a questionnaire asynchronously.
Choose Found if: You want behavioral coaching integrated into your treatment, you're thinking about what happens after you stop GLP-1 medication, or you prefer an all-in-one program that pairs medication with lifestyle support.
| Mochi Health | Found | |
|---|---|---|
| All-in monthly cost (compounded/budget pathway) | ~$178/mo (membership + semaglutide) | ~$149/mo+ (orforglipron, pending approval, + program fee) |
| Consultation type | Synchronous video with obesity specialist | Video + async; behavioral coaching included |
| Provider credentials | Board-certified obesity medicine | Board-certified obesity medicine |
| Registered dietitian | ✅ Included | ❌ Not included |
| Behavioral coaching | ❌ | ✅ Core part of program |
| Non-GLP-1 medications | ✅ (topiramate, bupropion, metformin, orlistat) | ❌ GLP-1 only |
| Insurance support | ✅ Prior authorization for brand medications | ✅ Prior authorization for brand medications |
| Lab work included | ❌ Recommended at additional cost | ❌ |
| HSA/FSA accepted | ✅ | ✅ |
| States covered | 49 | 50 |
How do Mochi Health and Found compare on price?
Both programs land around $150–$180/month depending on your medication pathway — but what you're paying for differs.
| Mochi Health | Found | |
|---|---|---|
| Compounded semaglutide | $178/mo ($79 membership + $99 medication) | Not offered (FDA enforcement) |
| Orforglipron (pending approval) | Not announced | ~$149/mo + program fee |
| Oral Wegovy (semaglutide) | Not offered | $199–299/mo + program fee |
| Brand Wegovy (injectable) | Insurance + membership fee | Insurance-dependent |
| Zepbound (tirzepatide) | $278/mo ($79 + $199) | $299/mo + program fee |
| Membership / program fee | $79/mo (covers visits and dietitian) | Charged separately on top of medication |
| Shipping | Free | Free |
Pricing note: Mochi's two-part model separates membership ($79/mo) from medication. Found charges a program fee on top of medication. Neither structure is better or worse — but you need to add the components together to get your real monthly cost. Mochi's all-in compounded semaglutide figure ($178/mo) has been stable since 2025. Found's orforglipron pricing ($149/mo + fee) is based on announced pricing, pending the April 10, 2026 PDUFA decision.
Pricing last verified April 2026. We update pricing data monthly.
What kind of care does each program offer?
| Mochi Health | Found | |
|---|---|---|
| Consultation format | Synchronous video with obesity specialist | Video and async; coaching check-ins ongoing |
| Behavioral coaching | ❌ | ✅ Included in program |
| Registered dietitian | ✅ Included in membership | ❌ |
| Community support | ❌ | ✅ Group forums |
| Provider credentials | Board-certified obesity medicine | Board-certified obesity medicine |
| Follow-up structure | Video follow-ups as needed | Regular coaching check-ins + physician visits |
Mochi Health's clinical model centers on the obesity specialist visit. Your provider conducts a live video consultation — not an async questionnaire review — adjusts your titration in real time, and has the clinical training to interpret complex metabolic history. A registered dietitian is also included in your membership — few programs at this price include it.
Found's care model adds a behavioral layer that Mochi doesn't offer. Medication is prescribed by board-certified obesity medicine physicians, but the program also includes regular coaching check-ins, community forums, and lifestyle guidance. Found's premise: GLP-1 medications produce results on their own, but behavioral habits are what prevent weight regain after stopping. The STEP 1 extension trial found participants regained approximately 67% of lost weight within a year of discontinuing semaglutide — and Found's coaching is explicitly designed around this problem.
The right choice depends on what you need from a program.
Which medications does each program prescribe?
| Medication | Mochi Health | Found |
|---|---|---|
| Compounded semaglutide (injectable) | ✅ $99/mo flat rate | ❌ (FDA enforcement) |
| Orforglipron (oral, pending approval) | Not announced | ✅ $149/mo announced |
| Oral Wegovy (semaglutide pill) | ❌ | ✅ $199–299/mo |
| Brand Wegovy (injectable, 2.4mg) | ✅ via insurance | ✅ via insurance |
| Brand Wegovy HD (7.2mg) | ❌ announced | ✅ via insurance |
| Brand Zepbound (tirzepatide) | ✅ $199/mo or via insurance | ✅ $299/mo or via insurance |
| Topiramate | ✅ | ❌ |
| Bupropion | ✅ | ❌ |
| Metformin | ✅ | ❌ |
| Orlistat | ✅ | ❌ |
Mochi's access to non-GLP-1 alternatives is a practical clinical advantage: not every patient responds to GLP-1s, and a provider willing to prescribe topiramate or bupropion when appropriate is making individualized decisions rather than defaulting to a single pathway.
Found's strength is its branded medication coverage. They carry oral Wegovy and the high-dose Wegovy HD formulation (20.7% mean weight loss in SURMOUNT trials), plus early access to orforglipron if it receives approval on April 10. For patients who can't use or don't want compounded medications, Found's branded lineup is broader.
How does the onboarding process compare?
Mochi Health intake:
- Complete a medical questionnaire covering health history, BMI, current medications, and weight loss history
- Schedule a live video consultation with a board-certified obesity medicine specialist
- Your provider prescribes a treatment plan and titration schedule — same-day in most cases
- Medication ships from a partner pharmacy (typically within 2 days)
- Ongoing video follow-ups and dietitian access as part of membership
Found intake:
- Complete a comprehensive questionnaire — includes eating patterns, sleep, stress, physical activity, and weight history (more behavioral depth than Mochi's intake)
- Matched with a board-certified obesity medicine provider; video and async consultations available
- Personalized treatment plan combining medication and behavioral goals
- Regular coaching check-ins begin alongside your medication
- Medication ships (5–7 business days — slower than Mochi)
Found's intake takes longer and asks more behavioral questions by design. If you're in a hurry to get started, Mochi typically moves faster from intake to prescription.
Who is Mochi Health best for?
- Patients who want a real clinical conversation — not a questionnaire reviewed asynchronously — with a specialist who can interpret complex metabolic history
- Those titrating to higher GLP-1 doses, who benefit from Mochi's flat-rate pricing model ($99/mo semaglutide at all doses, including maintenance)
- Patients who value having a registered dietitian available as part of their program
- People with metabolic complexity — insulin resistance, prior treatment failures, multiple comorbidities — who need individualized clinical judgment
- Patients exploring non-GLP-1 alternatives if GLP-1 isn't appropriate or effective
Read our full Mochi Health review for more detail on protocols, patient experience, and pricing.
Who is Found best for?
- Patients who want behavioral support alongside medication — particularly those with a history of weight cycling or who are thinking about long-term maintenance
- People concerned about weight regain after stopping GLP-1 medication (a real and common clinical issue)
- Patients who prefer an integrated program structure over a standalone prescription service
- Those seeking access to orforglipron or oral Wegovy as their primary medication pathway
- Medicare patients seeking GLP-1 access at lower copay through Found's Medicare Bridge support
Read our full Found weight loss review for more detail on coaching model, medication options, and pricing.
Frequently Asked Questions
Is Mochi Health or Found cheaper? It depends on your medication. For compounded semaglutide, Mochi Health runs about $178/month (membership + medication). Found no longer offers compounded semaglutide due to FDA enforcement. If orforglipron receives FDA approval on April 10, 2026, Found's budget pathway would be $149/month plus program fee — potentially lower all-in than Mochi depending on the fee amount. For branded medications, costs are similar between the two.
Does Mochi Health include coaching? No. Mochi includes registered dietitian access (a significant benefit at its price point), but not the behavioral coaching or community support that Found provides. Found's coaching model is more structured and ongoing.
Does Found use real doctors? Yes. Found uses board-certified obesity medicine physicians — the same specialist credential Mochi Health uses. The clinical foundation is comparable; the difference is in what surrounds the prescription (coaching vs. dietitian access).
Which program is better for someone who has failed weight loss before? Patients with multiple prior failed attempts may benefit from Mochi's deeper clinical oversight — obesity medicine specialists are trained to evaluate why prior approaches didn't work and to design individualized treatment plans. Patients who've struggled with behavior change and regain may benefit more from Found's coaching structure. In practice, the right choice depends on why prior attempts failed.
Can I switch between Mochi Health and Found? Yes — both are month-to-month programs. You'd need to discontinue one before starting the other, and your new provider would need to review your medical history to determine appropriate dosing on continuity of GLP-1 treatment.
Does either program offer compounded semaglutide? Mochi Health still offers compounded semaglutide at $99/month (flat rate, all doses). Found discontinued compounded GLP-1s following FDA enforcement actions and now prescribes brand-name medications only. The regulatory landscape continues to evolve — check both providers' current offerings before enrolling.
Related Comparisons
- Mochi Health vs Hims GLP-1 — How Mochi compares to the async budget provider
- Mochi Health vs Henry Meds GLP-1 — Specialist care vs volume-focused pricing
- Found vs Calibrate Weight Loss — Found vs the premium behavioral program
- Found vs Henry Meds for GLP-1 — Found's clinical program vs cash-pay Henry Meds
Data Sources & Methodology
Pricing and protocol data sourced from Mochi Health and Found public websites, verified via checkout flow, April 2026. Clinical trial data cited from published literature (Wilding et al. 2022, STEP 1 extension). Telehealth Ally has no commercial relationship with either provider. Rankings and ratings are editorial-only.
Related Guides
Best GLP-1 Options After Foundayo Approval: Oral vs Injectable 2026
Read guide →Best Telehealth Providers for Tirzepatide 2026: Ranked by Price and Care
The best telehealth providers for tirzepatide in 2026, ranked by price, protocol, and care quality. From $278/month compounded to brand Zepbound via insurance. No provider paid for placement.
Read guide →Is Compounded Semaglutide Legal and Safe in 2026?
Is compounded semaglutide still legal? We break down the current FDA rules, 30 new warning letters, SAFE Drugs Act, Hims exiting compounded, and what this means for your prescription.
Read guide →Compounded Tirzepatide 2026: What's Happening and What Patients Should Do
Compounded tirzepatide is under active FDA enforcement as of April 2026 — supply is declining but not yet at zero. The 503B enforcement discretion ended over a year ago (March 2025); the FDA has now issued 50+ warning letters including a 30-letter batch in April 2026. Here's what patients need to know and what to do.
Read guide →